Ophiomics was founded in 2015 by José Pereira Leal and Joana Cardoso Vaz. Initially it was a clinical testing laboratory focused in oncology, that pioneered, in collaboration with Centro de Medicina Laboratorial Germano de Sousa, the routine somatic sequencing, liquid biopsies, and high throughput sequencing for cancer genetics in Portugal. The yearn to pursue innovation by both founders led to the development of a new biomarker-based algorithm to stratify liver cancer patients for curative-intent liver transplantation in collaboration with the transplant surgeon Hugo Pinto Marques. This paved the way for the launch of Ophiomics (2.0) - a company focused on developing innovative AI-assisted In Vitro Diagnostics Medical Devices - funded by the first generation of the ultra-competitive EIC Accelerator grants. Two and a half years later, we launched ou first product, HepatoPredict. This was just the beginning!